In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding

Furio Colivicchi

doi:10.7326/J21-0014

In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding

Ann Intern Med. 2022 Feb;175(2):JC22. doi: 10.7326/J21-0014. Epub 2022 Feb 1.

Author

Furio Colivicchi¹

Affiliation

¹ San Filippo Neri Hospital, Rome, Italy (F.C.).

PMID: 35099999
DOI: 10.7326/J21-0014

Abstract

Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385:2150-60. 34449183.

Publication types

Comment

MeSH terms

Anticoagulants / adverse effects
Atrial Fibrillation* / drug therapy
Atrial Fibrillation* / physiopathology
Hemorrhage / chemically induced
Humans
Pyridines / adverse effects
Thiazoles / adverse effects
Transcatheter Aortic Valve Replacement* / adverse effects

Substances

Anticoagulants
Pyridines
Thiazoles
edoxaban